Invesco Biotechnology & Genome ETF (PBE) Research
The Invesco Biotechnology & Genome ETF (PBE) seeks to replicate the performance of the Dynamic Biotech & Genome Intellidex Index. This fund typically allocates a minimum of 90% of its total assets to the securities comprising the underlying index. The Index is constructed to achieve capital appreciation by thoroughly evaluating companies based on several investment criteria, including their price momentum, earnings growth, overall quality, management decisions, and valuation. It consists of 30 U.S.-based companies within the biotechnology and genome sectors. These companies are primarily involved in the research, development, manufacture, and distribution of various biotechnological products, services, and processes, or they are businesses that stand to gain significantly from scientific and technological breakthroughs in biotechnology and genetic engineering. Both the ETF and its benchmark index undergo quarterly rebalancing and reconstitution in February, May, August, and November.
Market snapshot
- Symbol
- PBE
- Price
- $84.52
- Day change
- +0.09%
- Market cap
- $257.8M
- 52-week range
- 62.63-85.73
- Sector
- Financial Services
- Industry
- Asset Management
Peer companies
- Avantis Responsible International Equity ETF (AVSD)
- Convergence Long/Short Equity ETF (CLSE)
- Dimensional - Emerging Markets ex China Core Equity ETF (DEXC)
- First Trust Dow 30 Equal Weight ETF (EDOW)
- NYLI Candriam International Equity ETF (IQSI)
- Inspire Small/Mid Cap ETF (ISMD)
- Janus Henderson Small Cap Growth Alpha ETF (JSML)
- Invesco S&P 500 Equal Weight Consumer Discretionary ETF (RSPD)
Open Invesco Biotechnology & Genome ETF (PBE) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.